2022-03-012023-02-282023-02-28false06828498TOTALLY PHARMACY LTD2023-11-14iso4217:GBPxbrli:pure068284982022-03-01068284982023-02-28068284982022-03-012023-02-28068284982021-03-01068284982022-02-28068284982021-03-012022-02-2806828498bus:SmallEntities2022-03-012023-02-2806828498bus:AuditExempt-NoAccountantsReport2022-03-012023-02-2806828498bus:FullAccounts2022-03-012023-02-2806828498bus:PrivateLimitedCompanyLtd2022-03-012023-02-2806828498core:WithinOneYear2023-02-2806828498core:AfterOneYear2023-02-2806828498core:WithinOneYear2022-02-2806828498core:AfterOneYear2022-02-2806828498core:ShareCapital2023-02-2806828498core:SharePremium2023-02-2806828498core:RevaluationReserve2023-02-2806828498core:OtherReservesSubtotal2023-02-2806828498core:RetainedEarningsAccumulatedLosses2023-02-2806828498core:ShareCapital2022-02-2806828498core:SharePremium2022-02-2806828498core:RevaluationReserve2022-02-2806828498core:OtherReservesSubtotal2022-02-2806828498core:RetainedEarningsAccumulatedLosses2022-02-2806828498core:LandBuildings2023-02-2806828498core:PlantMachinery2023-02-2806828498core:Vehicles2023-02-2806828498core:FurnitureFittings2023-02-2806828498core:OfficeEquipment2023-02-2806828498core:NetGoodwill2023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2023-02-2806828498core:ListedExchangeTraded2023-02-2806828498core:UnlistedNon-exchangeTraded2023-02-2806828498core:LandBuildings2022-02-2806828498core:PlantMachinery2022-02-2806828498core:Vehicles2022-02-2806828498core:FurnitureFittings2022-02-2806828498core:OfficeEquipment2022-02-2806828498core:NetGoodwill2022-02-2806828498core:IntangibleAssetsOtherThanGoodwill2022-02-2806828498core:ListedExchangeTraded2022-02-2806828498core:UnlistedNon-exchangeTraded2022-02-2806828498core:LandBuildings2022-03-012023-02-2806828498core:PlantMachinery2022-03-012023-02-2806828498core:Vehicles2022-03-012023-02-2806828498core:FurnitureFittings2022-03-012023-02-2806828498core:OfficeEquipment2022-03-012023-02-2806828498core:NetGoodwill2022-03-012023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2022-03-012023-02-2806828498core:ListedExchangeTraded2022-03-012023-02-2806828498core:UnlistedNon-exchangeTraded2022-03-012023-02-2806828498core:MoreThanFiveYears2022-03-012023-02-2806828498core:Non-currentFinancialInstruments2023-02-2806828498core:Non-currentFinancialInstruments2022-02-2806828498dpl:CostSales2022-03-012023-02-2806828498dpl:DistributionCosts2022-03-012023-02-2806828498core:LandBuildings2022-03-012023-02-2806828498core:PlantMachinery2022-03-012023-02-2806828498core:Vehicles2022-03-012023-02-2806828498core:FurnitureFittings2022-03-012023-02-2806828498core:OfficeEquipment2022-03-012023-02-2806828498dpl:AdministrativeExpenses2022-03-012023-02-2806828498core:NetGoodwill2022-03-012023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2022-03-012023-02-2806828498dpl:GroupUndertakings2022-03-012023-02-2806828498dpl:ParticipatingInterests2022-03-012023-02-2806828498dpl:GroupUndertakingscore:ListedExchangeTraded2022-03-012023-02-2806828498core:ListedExchangeTraded2022-03-012023-02-2806828498dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-03-012023-02-2806828498core:UnlistedNon-exchangeTraded2022-03-012023-02-2806828498dpl:CostSales2021-03-012022-02-2806828498dpl:DistributionCosts2021-03-012022-02-2806828498core:LandBuildings2021-03-012022-02-2806828498core:PlantMachinery2021-03-012022-02-2806828498core:Vehicles2021-03-012022-02-2806828498core:FurnitureFittings2021-03-012022-02-2806828498core:OfficeEquipment2021-03-012022-02-2806828498dpl:AdministrativeExpenses2021-03-012022-02-2806828498core:NetGoodwill2021-03-012022-02-2806828498core:IntangibleAssetsOtherThanGoodwill2021-03-012022-02-2806828498dpl:GroupUndertakings2021-03-012022-02-2806828498dpl:ParticipatingInterests2021-03-012022-02-2806828498dpl:GroupUndertakingscore:ListedExchangeTraded2021-03-012022-02-2806828498core:ListedExchangeTraded2021-03-012022-02-2806828498dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-03-012022-02-2806828498core:UnlistedNon-exchangeTraded2021-03-012022-02-2806828498core:NetGoodwill2023-02-2806828498core:IntangibleAssetsOtherThanGoodwill2023-02-2806828498core:LandBuildings2023-02-2806828498core:PlantMachinery2023-02-2806828498core:Vehicles2023-02-2806828498core:FurnitureFittings2023-02-2806828498core:OfficeEquipment2023-02-2806828498core:AfterOneYear2023-02-2806828498core:WithinOneYear2023-02-2806828498core:ListedExchangeTraded2023-02-2806828498core:UnlistedNon-exchangeTraded2023-02-2806828498core:ShareCapital2023-02-2806828498core:SharePremium2023-02-2806828498core:RevaluationReserve2023-02-2806828498core:OtherReservesSubtotal2023-02-2806828498core:RetainedEarningsAccumulatedLosses2023-02-2806828498core:NetGoodwill2022-02-2806828498core:IntangibleAssetsOtherThanGoodwill2022-02-2806828498core:LandBuildings2022-02-2806828498core:PlantMachinery2022-02-2806828498core:Vehicles2022-02-2806828498core:FurnitureFittings2022-02-2806828498core:OfficeEquipment2022-02-2806828498core:AfterOneYear2022-02-2806828498core:WithinOneYear2022-02-2806828498core:ListedExchangeTraded2022-02-2806828498core:UnlistedNon-exchangeTraded2022-02-2806828498core:ShareCapital2022-02-2806828498core:SharePremium2022-02-2806828498core:RevaluationReserve2022-02-2806828498core:OtherReservesSubtotal2022-02-2806828498core:RetainedEarningsAccumulatedLosses2022-02-2806828498core:NetGoodwill2021-03-0106828498core:IntangibleAssetsOtherThanGoodwill2021-03-0106828498core:LandBuildings2021-03-0106828498core:PlantMachinery2021-03-0106828498core:Vehicles2021-03-0106828498core:FurnitureFittings2021-03-0106828498core:OfficeEquipment2021-03-0106828498core:AfterOneYear2021-03-0106828498core:WithinOneYear2021-03-0106828498core:ListedExchangeTraded2021-03-0106828498core:UnlistedNon-exchangeTraded2021-03-0106828498core:ShareCapital2021-03-0106828498core:SharePremium2021-03-0106828498core:RevaluationReserve2021-03-0106828498core:OtherReservesSubtotal2021-03-0106828498core:RetainedEarningsAccumulatedLosses2021-03-0106828498core:AfterOneYear2022-03-012023-02-2806828498core:WithinOneYear2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:CostValuation2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-012023-02-2806828498core:Non-currentFinancialInstrumentscore:CostValuation2023-02-2806828498core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-2806828498core:Non-currentFinancialInstrumentscore:CostValuation2022-02-2806828498core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-02-2806828498core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-02-2806828498bus:Director12022-03-012023-02-2806828498bus:Director22022-03-012023-02-2806828498core:FurnitureFittingsToolsEquipment2022-02-2806828498core:FurnitureFittingsToolsEquipment2022-03-012023-02-2806828498core:FurnitureFittingsToolsEquipment2023-02-28

TOTALLY PHARMACY LTD

Registered Number
06828498
(England and Wales)

Unaudited Financial Statements for the Year ended
28 February 2023

TOTALLY PHARMACY LTD
Company Information
for the year from 1 March 2022 to 28 February 2023

Directors

SAUNDH, Kamaljeet Singh
SAUNDH, Rajpal Kaur

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

06828498 (England and Wales)
TOTALLY PHARMACY LTD
Balance Sheet as at
28 February 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Intangible assets7240,267250,867
Tangible assets8117,37625,485
Investments9133,333123,178
490,976399,530
Current assets
Stocks1122,17019,130
Debtors12752,488436,856
Cash at bank and on hand138,685518,729
913,343974,715
Creditors amounts falling due within one year13(429,706)(544,942)
Net current assets (liabilities)483,637429,773
Total assets less current liabilities974,613829,303
Creditors amounts falling due after one year14(22,831)-
Net assets951,782829,303
Capital and reserves
Called up share capital160,451160,451
Profit and loss account791,331668,852
Shareholders' funds951,782829,303
The financial statements were approved and authorised for issue by the Board of Directors on 14 November 2023, and are signed on its behalf by:
SAUNDH, Kamaljeet Singh
Director
Registered Company No. 06828498
TOTALLY PHARMACY LTD
Notes to the Financial Statements
for the year ended 28 February 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
The principal activity of the company in the year under review was that of pharmaceutical goods and services
4.Basis of measurement used in financial statements
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
5.Accounting policies
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery25
Fixtures and fittings25
Vehicles25
Office Equipment25
Intangible assets policy
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Goodwill is being amortised evenly over its estimated useful life of 25 years.
Stocks policy
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Investments policy
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
6.Employee information

20232022
Average number of employees during the year108
7.Intangible assets

Goodwill

Other

Total

£££
Cost or valuation
At 01 March 22265,00076,705341,705
At 28 February 23265,00076,705341,705
Amortisation and impairment
At 01 March 2214,13376,70590,838
Charge for year10,600-10,600
At 28 February 2324,73376,705101,438
Net book value
At 28 February 23240,267-240,267
At 28 February 22250,867-250,867
8.Property, plant and equipment

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 March 229,11149,76440,0029,871108,748
Additions71,03234,0105,0721,936112,050
At 28 February 2380,14383,77445,07411,807220,798
Depreciation and impairment
At 01 March 223,85839,42233,0236,96083,263
Charge for year8,4818,2542,48494020,159
At 28 February 2312,33947,67635,5077,900103,422
Net book value
At 28 February 2367,80436,0989,5673,907117,376
At 28 February 225,25310,3426,9792,91125,485
9.Fixed asset investments

Other investments1

Total

££
Cost or valuation
At 01 March 22123,178123,178
Revaluations10,15510,155
At 28 February 23133,333133,333
Net book value
At 28 February 23133,333133,333
At 28 February 22123,178123,178

Notes

1Other investments other than loans
10.Description of nature of transactions and balances with related parties
At the yearend, Totally Investments Ltd owed £434,318 (2022: £133,868) to TotallyPharmacy Ltd. The companies are related as Kamaljeet Saundh and Rajpal Saundh are the directors in both companies.
11.Stocks

2023

2022

££
Finished goods22,17019,130
Total22,17019,130
12.Debtors

2023

2022

££
Trade debtors / trade receivables307,676196,774
Amounts owed by group undertakings434,318133,868
Other debtors7,626104,433
Prepayments and accrued income2,8681,781
Total752,488436,856
13.Creditors within one year

2023

2022

££
Trade creditors / trade payables130,885120,322
Bank borrowings and overdrafts4,396-
Taxation and social security24,58444,320
Payments received on account83,61881,585
Other creditors153,550265,496
Accrued liabilities and deferred income32,67333,219
Total429,706544,942
14.Creditors after one year

2023

2022

££
Bank borrowings and overdrafts22,831-
Total22,831-